Comparative evaluation of Oxford Nanopore Technologies’ adaptive sampling and the Twist long-read PGx panel for pharmacogenomic profiling
Frontiers in Pharmacology · 09.09.2025 · 16
DOI: 10.3389/fphar.2025.1653999 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.09.2025. Verfasst von Koen Deserranno und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmaceutical Biotechnology, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bijzonder Onderzoeksfonds UGent.
Abstract (Originalsprache)
Clinical pharmacogenomics (PGx) testing strategies are mainly based on targeted PCR, microarrays, or short-read sequencing. These methods perform well for detecting known single-nucleotide variants (SNVs), small insertions/deletions (indels), and certain copy number variants (CNVs), but they fall short in resolving complex structural variants (SVs), particularly in complex pharmacogenes such as CYP2D6 . Therefore, we previously developed a targeted PGx test based on long-read Oxford Nanopore Technologies (ONT) sequencing. Harnessing adaptive sampling (AS) for in silico enrichment of a panel of PGx genes, we illustrated superior performance in star-allele calling compared to the Genetic Testing Reference Materials Program (GeT-RM) truth set. However, accurate diplotyping of CYP2D6 remained challenging. In this work, we adopted the latest basecalling, variant calling, phasing, and star-allele calling tools on our pre-existing data from the HG001, HG01190, NA19785, HG002, and HG005 reference samples. Additionally, we benchmarked the results to public data obtained using the long-read compatible Twist Alliance PGx panel. The re-analyzed ONT-AS data demonstrated correct CYP2D6 star-alleles compared to the GeT-RM truth set. Upon benchmarking to the Twist Alliance PGx panel, perfect star-allele matching was obtained between our panel and the Twist PGx panel for all included Clinical Pharmacogenomics Implementation Consortium (CPIC) Level A genes. However, our ONT-AS panel demonstrated superior variant phasing, resulting in three times more variants per phasing block. These findings confirm the robustness of ONT-AS for targeted long-read PGx applications and highlight its potential to support more accurate pharmacogenomic testing, particularly for structurally complex genes like CYP2D6 .
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Pharmaceutical Biotechnology, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Förderung
- Bijzonder Onderzoeksfonds UGent
Zitieren
APA
Deserranno, K., Tilleman, L., Deforce, D., & Van Nieuwerburgh, F. (2025). Comparative evaluation of Oxford Nanopore Technologies’ adaptive sampling and the Twist long-read PGx panel for pharmacogenomic profiling. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1653999
Vancouver
Deserranno K, Tilleman L, Deforce D, Van Nieuwerburgh F. Comparative evaluation of Oxford Nanopore Technologies’ adaptive sampling and the Twist long-read PGx panel for pharmacogenomic profiling. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1653999
BibTeX
@article{Deserranno2025,
author = {Deserranno, Koen and Tilleman, Laurentijn and Deforce, Dieter and Van Nieuwerburgh, Filip},
title = {Comparative evaluation of Oxford Nanopore Technologies’ adaptive sampling and the Twist long-read PGx panel for pharmacogenomic profiling},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1653999}
}
EUVIMED